Fate Therapeutics Inc (FATE): Forvard narx/daromad multiplikatori
Fate Therapeutics, Inc. (FATE) o'zining ilmiy xodimlarini saxovatli RSU va budjetlar bilan ta'minlash orqali immunoterapiyalarni ishlab chiqish uchun yetakchi biologlarni jalb qilmoqda. Klinik xarajatlar mavjud naqd pul zaxiralari hisobidan qoplanmoqda, bu holat forward P/S dinamikasida aks etgan bo'lib, u yerda so'nggi qiymat 33.10 deb qayd etilgan. Biznes daromadlari grantlar hamda onkologik davolash vositalarini ishlab chiqish uchun strategik farmatsevtika hamkorlaridan kelgan to'lovlarga asoslangan.
Fate Pharma (FATE) kompaniyasining tahliliy kesimlari
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- birja kapitallashuvi ma'lumotlari:
- biznesning balans baholash tafsilotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Umumiy qarzning xususiy kapitalga nisbati Fate Therapeutics, Inc.|FATE - Uzoq muddatli kreditlarning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Fate Therapeutics, Inc.|FATE - Jamlangan qarz majburiyatlari|Balans kapitallashuviga qarzlar Fate Pharma|FATE - Uzoq muddatli qarz|Kompaniyaning qisqa muddatli qarzi Fate Therapeutics|Tezkor likvidlik koeffitsiyenti fatetherapeutics.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
FATE - Sof foyda|Kutilayotgan foyda Fate Therapeutics, Inc.|FATE - Kapitalizatsiyaning sof foydaga nisbati|Forvard P/E multiplikatori Fate Therapeutics Corp|FATE - O‘sish sur’atiga tuzatilgan narx-foyda|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti Fate Pharma|FATE - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda Fate Therapeutics|FATE - So'nggi to'rtta chorak uchun bir aksiya uchun foyda|Choraklik EPS foyda o'sishi fatetherapeutics.com|FATE - Bu yil bir aksiya uchun sof foydaning kutilayotgan o'sishi|Keyingi yil uchun foyda o'sishi prognozi Fate Therapeutics, Inc.
- tushum va sotuvlar tafsilotlari:
Kompaniyaning jamlanma tahlili:Fate Therapeutics FATE
Fate Therapeutics, Inc. (FATE) o'zining iPSC platformasini ishlab chiqayotgan biotexnologiya sektori uchun ushbu ko'rsatkich kelajakdagi daromadlar bo'yicha bozor kutganlarini baholash vositasi bo'lib xizmat qiladi. Forward P/S ko'rsatkichi joriy bozor kapitalizatsiyasining kutilayotgan yillik savdolarga nisbati sifatida hisoblanadi, bu esa investorlarga ushbu grafikdan aktiv qiymatini yangi ittifoqlar va klinik sinovlar muvaffaqiyatlari salohiyati bilan solishtirish uchun foydalanish imkonini beradi.
Raqobatchilar tahlili
Forvard P/S multiplikatori ONC (BeiGene)|Forvard P/S multiplikatori Halozyme Therapeutics, Inc. HALO|RVMD: Forvard narx/daromad multiplikatori|Ascentage Pharma Corp - Narxning kutilayotgan daromadga nisbati|CGON: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati urogen.com (URGN)|Forvard narx/daromad multiplikatori BCAX|PSNL: Sotuvga nisbatan forvard narx|Forvard narx/daromad multiplikatori ERAS (Erasca Corp)|Narxning kutilayotgan daromadga nisbati DCTH|Forvard P/S multiplikatori YMAB (Y-mAbs Therapeutics)|Sotuvga nisbatan forvard narx AURA|Candel - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Accuray Inc|sellaslifesciences.com (SLS) - Narxning prognoz qilingan daromadga nisbati|Actuate Therapeutics Inc - Sotuvga nisbatan forvard narx|CTOR (Citius Oncology, Inc.) - Forvard P/S multiplikatori|Forvard P/S multiplikatori TuHURA|Narxning prognoz qilingan daromadga nisbati Protara Therapeutics, Inc. (TARA)|WHWK: Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Bozor kapitallashuvining kelajakdagi daromadga nisbati|XBIT: Forvard narx/daromad multiplikatori|CVM - Forvard P/S multiplikatori|OSTX (OS Therapies) - Forvard narx/daromad multiplikatori|RADX: Narxning kutilayotgan daromadga nisbati|ARTV (Artiva Biotherapeutics Inc.) - Forvard P/S multiplikatori|Adlai Nortye Limited (ANL) - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Forvard P/S multiplikatori VERU|Forvard narx/daromad multiplikatori tempesttx.com TPST|Narxning prognoz qilingan daromadga nisbati Xilio Therapeutics XLO|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Renovaro Biosciences (RENB)|MURA: Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx KAPA (Kairos Pharma Ltd)|OKUR: Forvard P/S multiplikatori|GDTC - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Narxning prognoz qilingan daromadga nisbati Curis Inc.|Kapitalizatsiyaning prognoz qilingan daromadga nisbati APLM (Apollomics Corp)|Forvard P/S multiplikatori THAR|Forvard narx/daromad multiplikatori advanbiomed.com ADVB|Genprex, Inc. - Forvard narx/daromad multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Calidi Biotherapeutics Inc. (CLDI)|Sunshine Biopharma, Inc. - Forvard P/S multiplikatori|Kelajakdagi narxning daromadga nisbati XBIO|SLRX: Forvard P/S multiplikatori|Kitov Pharma (PPBT) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori AONC|BGNE (beigene.com) - Narxning kutilayotgan daromadga nisbati|Forvard P/S multiplikatori CKPT|ELEV - Bozor kapitallashuvining kelajakdagi daromadga nisbati|Forvard P/S multiplikatori ICAD (iCAD)|IKNA - Forvard narx/daromad multiplikatori|Notable Labs, Ltd. - Forvard P/S multiplikatori|VIRX - Forvard P/S multiplikatori|MorphoSys (MOR) - Narxning prognoz qilingan daromadga nisbati|Kapitalizatsiyaning prognoz qilingan daromadga nisbati NAYA|AAPGV (Ascentage Pharma Group Ltd) - Forvard P/S multiplikatori
